A recent study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1 signaling regulates mammalian life span.” This study was published in the 2 October 2009 issue of the Journal “Science” (I.F: 31.477 )by Prof Dominic J. Withers, Dr. Selman C and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Life-span extension therapy: EMX2 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Life-span extension therapy: EMX2 inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span via up regulation of its target gene, 3/April/2015, 18.24, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Significance: This study suggests that EMX2, by increasing the expression of its target gene, it may decrease the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase). Thereby, it may promote resistance to bone, immune, and motor dysfunction. Thus, pharmacological formulations encompassing “EMX2 or its activators“ may be used to extend the life span of an individual.
Undisclosed information: How EMX2 decreases the expression of p70S6 Kinase